These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22278138)

  • 41. Direct renin inhibition with aliskiren in hypertension and target organ damage.
    Müller DN; Luft FC
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):221-8. PubMed ID: 17699210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
    Stanton AV; Dicker P; O'Brien ET
    Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
    Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M
    J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Zoppi A; Maffioli P; Monti C; Lazzari P; Mugellini A; Derosa G
    Diabetes Obes Metab; 2012 Apr; 14(4):341-7. PubMed ID: 22074122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
    J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?
    Pimenta E; Oparil S
    Cardiol Clin; 2008 Nov; 26(4):527-35. PubMed ID: 18929229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversibility of the effects of aliskiren in the renal versus systemic circulation.
    Schneider MP; Janka R; Ziegler T; Raff U; Ritt M; Ott C; Veelken R; Uder M; Schmieder RE
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):258-64. PubMed ID: 22173856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus.
    Seki Y; Morimoto S; Kimura S; Takano N; Yamashita K; Bokuda K; Sasaki N; Watanabe D; Ichihara A
    Kidney Blood Press Res; 2023; 48(1):688-700. PubMed ID: 37866351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
    J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
    Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
    Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.
    Fukutomi M; Hoshide S; Mizuno H; Kario K
    Am J Hypertens; 2014 Jan; 27(1):14-20. PubMed ID: 24008122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does blockade of the renin angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?
    Ruzicka M; Coletta E; Leenen FH
    Am J Hypertens; 2007 Nov; 20(11):1202-8. PubMed ID: 17954368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Renin and the heart].
    Ural D; Cetin M
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():23-7. PubMed ID: 20019473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
    Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
    Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.